Patent application number | Description | Published |
20090186369 | POLYSACCHARIDE-PROTEIN BINDING MODEL AND NANO-FIBRIL FORMATION OF A STARCH BINDING DOMAIN - The present invention relates to a polysaccharide-protein binding model of SBD, and a fibril-forming 14-residue peptide consisting of X | 07-23-2009 |
20100016239 | HEPARIN BINDING MOTIF AND USE THEREOF - A method for reducing cytotoxicity of eosinophil derived toxins comprising administering to a subject an effective amount of heparin, heparan sulfate, a potent heparanase inhibitor or a polypeptide which has sequence as follows: BZBXBX, XBBBXXBX, XBBXBX, BBXXBBBXXBB, BXBBXB, XBBBXXBBBXXBBX, or TXXBXXTBXXXTBB, wherein X represents any amino acid, Z represents an aromatic amino acid, and B represents a basic amino acid and T represents a turn. | 01-21-2010 |
20100048880 | Starch Binding Domain and Use Thereof - The present invention relates to a starch binding domain, a recombinant protein and a complex thereof. The present invention also relates to a method for separating a recombinant protein comprising a starch binding domain of the present invention. | 02-25-2010 |
20100099855 | RECOMBINANT PROTEIN COMPRISING STARCH BINDING DOMAIN AND USE THEREOF - A recombinant protein is prepared comprising a polypeptide of interest and a starch binding domain (SBD). The said SBD is obtainable from glucoamylase of fungi genus | 04-22-2010 |
20100291540 | CARBOHYDRATE BINDING MODULE AND USE THEREOF - The present invention relates to an antibody mimetic of carbohydrate binding module (CBM) which specifically binds to an epitope on HIV glycoprotein. The present invention also relates to a method of detecting HIV glycoprotein. | 11-18-2010 |
20100291601 | CARBOHYDRATE BINDING MODULE AND USE THEREOF - The present invention relates to an antibody mimetic of carbohydrate binding module (CBM) which specifically binds to an epitope on HIV glycoprotein. The present invention also relates to a method of detecting HIV glycoprotein. | 11-18-2010 |
20100291656 | METHOD AND SYSTEM FOR PROTEIN PURIFICATION - The present invention provides a method and a system for protein purification using a starch binding protein (SBP)-tagged recombinant protein. SBP-binding matrixes are also disclosed in the invention to recover the SBP-tagged recombinant protein. Thus, purifying a target protein is re-usable, convenient and low cost by the present invention. | 11-18-2010 |
20110129853 | POLYSACCHARIDE-PROTEIN BINDING MODEL AND NANO-FIBRIL FORMATION OF A STARCH BINDING DOMAIN - A polysaccharide-protein binding model of SBD, and a fibril-forming 14-residue peptide consisting of X | 06-02-2011 |
20110280798 | Cell Penetrating Peptides for Intracellular Delivery - The present invention provides a cell penetrating peptide which has following sequence: NYBX | 11-17-2011 |
20120214730 | METHOD OF USING HEPARIN BINDING MOTIF FOR TREATING ASTHMA - The present invention is for an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 9 and using the peptide for treating asthma by reducing cytotoxicity of eosinophil derived toxins in bronchial epithelial cells of the subject suffers from asthma. The method comprises preparing a pharmaceutical composition having the peptide of SEQ ID NO: 9 and administering an effective amount of the composition to the subject. | 08-23-2012 |
20120225492 | Starch Binding Domain and Use Thereof - The present invention provides a method for identifying starch binding sites of starch binding domain in CBM family. The CBM family is consisting of CBM20, CBM21, CBM25, CBM26, CBM34, and CBM41. The method further comprises predicting starch binding sites of starch binding domain in CBM family using the identified starch binding sites of starch binding domain with same topology. | 09-06-2012 |
20120322082 | BIOMARKER FOR AMYOTROPHIC LATERAL SCLEROSIS AND DIAGNOSTIC KIT AND METHOD USED THEREOF - A diagnostic marker for determining of a patient with amyotrophic lateral sclerosis (ALS), comprising an autoantibody against a human protein HMGB1 is described. A diagnostic kit for determining of a patient with ALS, comprising: (a) an HMGB1 protein; and (b) an HMGB1 antibody standard is also presented. A method of determining ALS in a subject, comprising the steps: (a) detecting autoantibody against HMGB1 in a biological sample taken from the subject and normal control individuals; and (b) statistically comparing concentrations of the autoantibody against HMGB1 in the subject with that of the normal control individuals obtained from step (a); wherein a higher concentration of the autoantibody against HMGB1 in the subject than a cut-off concentration indicates the subject suffers from ALS is further described. | 12-20-2012 |
20130034877 | METHOD FOR INCREASING THERMAL STABILITY AND RETAINING ACTIVITY OF A PROTEIN - The present invention provides a method and a system for increasing thermal stability of a starch binding protein (SBP)-tagged recombinant protein. The present invention also provides a method for preventing releasing a SBP-tagged recombinant protein from a SBP-binding matrix and retaining an activity of the recombinant protein in aquatic environment. | 02-07-2013 |
20140072574 | METHODS OF USING IMMUNOMODULATING PEPTIDE FOR TREATING OR PREVENTING INFLAMMATORY RELATED DISEASES - A method of treating or preventing inflammatory related diseases in a subject in need thereof comprising administering to said subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is provided. A method for inhibiting cancer metastasis or growth of tumor in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is also provided. | 03-13-2014 |
20140127723 | METHOD FOR DETERMINING RISK OF AMYOTROPHIC LATERAL SCLEROSIS - The present invention provides a method of determining a risk for amyotrophic lateral sclerosis (ALS) in a subject, comprising the following steps: (1) measuring a concentration of an autoantibody against HMGB1 in a biological sample from the subject; and (2) comparing the measured concentration of the autoantibody against HMGB1 with a control value for autoantibody against HMGB1; wherein a difference between the measured concentration of the autoantibody against HMGB1 from the biological sample and the control value for autoantibody against HMGB1 is indicative of the risk of ALS in the subject. | 05-08-2014 |